Loading clinical trials...
Loading clinical trials...
A Phase 2 Study to Evaluate Subcutaneous Abatacept vs. Placebo in Diffuse Cutaneous Systemic Sclerosis- a Double-blind, Placebo-controlled, Randomized Controlled Trial.
Conditions
Interventions
Abatacept
Placebo
Locations
27
United States
Arthritis Associates of Southern California
Los Angeles, California, United States
University of California- Los Angeles
Los Angeles, California, United States
Stanford University
Redwood City, California, United States
Georgetown University
Washington D.C., District of Columbia, United States
Northwestern University
Chicago, Illinois, United States
Harvard Mass General
Boston, Massachusetts, United States
Start Date
September 1, 2014
Primary Completion Date
September 12, 2018
Completion Date
October 17, 2018
Last Updated
February 17, 2020
NCT05270668
NCT04986605
NCT04478994
NCT03198689
NCT00433186
Lead Sponsor
Dinesh Khanna, MD, MS
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions